CriticalAntidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B)×Opioid analgesic with dual mechanism
Updated · Methodology
Mechanism
Tapentadol is an opioid analgesic: it stimulates mu-opioid receptors and also inhibits noradrenaline reuptake (tapentadol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Phenelzine is a potent inhibitor of the enzyme monoamine oxidase (MAO), so it belongs to the MAO inhibitors (phenelzine label, US Food and Drug Administration, FDA). According to the Spanish tapentadol SmPC, MAO inhibitors can raise synaptic noradrenaline concentrations even further, which may lead to cardiovascular adverse reactions such as hypertensive crisis (tapentadol SmPC, AEMPS, section 4.5). According to the US tapentadol label, MAO inhibitors impair the metabolism of serotonin, and their interactions with opioids may present as serotonin syndrome or opioid toxicity (FDA tapentadol label, sections 5.7 and 7).
Symptoms
The documents do not say how this particular combination presents: they contraindicate it pre-emptively. Possible outcomes are a hypertensive crisis due to higher noradrenaline concentrations (tapentadol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5), serotonin syndrome, or opioid toxicity with respiratory depression and coma (tapentadol label, US Food and Drug Administration, FDA, section 7). Serotonin syndrome presents with mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high temperature), neuromuscular changes (overactive reflexes, poor coordination), nausea, vomiting and diarrhoea. It can be fatal and usually starts within several hours to a few days of combined use, but may start later (FDA tapentadol label, section 5.7). A hypertensive crisis presents with an occipital headache that may spread to the forehead, palpitations, neck stiffness or soreness, nausea, vomiting, sweating (sometimes with fever, sometimes with cold, clammy skin), dilated pupils and sensitivity to light. The heart rate may be fast or slow, sometimes with constricting chest pain. Intracranial bleeding has been reported with the rise in blood pressure (FDA phenelzine label, Warnings).
Management
The combination is contraindicated. The US tapentadol label prohibits taking tapentadol with monoamine oxidase (MAO) inhibitors or within 14 days of stopping them, and names phenelzine among the examples (tapentadol label, US Food and Drug Administration, FDA, sections 4 and 7). The Spanish tapentadol summary of product characteristics (SmPC) is milder: it advises avoiding tapentadol in patients who take MAO inhibitors or have taken them in the last 14 days (tapentadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Phenelzine is not authorised in Spain; its only official documents are from the US. Start tapentadol no earlier than 14 days after stopping phenelzine (tapentadol SmPC, AEMPS, section 4.5; FDA tapentadol label, sections 4 and 7), and do not start an MAO inhibitor while the patient is taking tapentadol (FDA tapentadol label, section 17). If an opioid is needed urgently, the US tapentadol label advises treating pain with other opioids, such as oxycodone, hydrocodone, oxymorphone or buprenorphine. Start with test doses, titrate small doses frequently and closely monitor blood pressure and signs of central nervous system and respiratory depression (FDA tapentadol label, section 7). If serotonin syndrome is suspected, stop tapentadol (FDA tapentadol label, section 5.7). If palpitations or frequent headaches occur, stop phenelzine at once; if a hypertensive crisis occurs, stop phenelzine and start lowering blood pressure immediately (FDA phenelzine label, Warnings). Before elective surgery, stop phenelzine at least 10 days in advance (FDA phenelzine label, Warnings).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Nardil (phenelzine sulfate tablets, USP) – prescribing information (2025)– FDA label, Parke-Davis Div of Pfizer, DailyMed setid 513a41d0-37d4-4355-8a6d-a2c643bce6fa, version 11, 06/2025, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Tapentadol, Palexia retard 100 mg (nº registro 73244), sección 4.5 (2026)– AEMPS, CIMA, nº registro 73244 (Palexia retard 100 mg comprimidos de liberación prolongada, Grünenthal Pharma), revisión 01/2026, secciones 4.4, 4.5 y 5.1
- FDA: Nucynta (tapentadol) tablets prescribing information (2025)– FDA, DailyMed setid 80938c30-9fe3-4c7d-9d9c-5476638cfb2d (Collegium Pharmaceutical), versión 7, vigente desde 30.12.2025, secciones 4, 5.7, 7 y 17